Association between asymmetric dimethylarginine level and central obesity among patients with acute myocardial infarction: exploratory cross-sectional study Authors: Ihab A Naser, Ammar MA AbuSaada, Riad K Al Qedra Published: 2026 ABSTRACT AbstractBackgroundAsymmetric dimethylarginine (ADMA), a competitive inhibitor of endothelial nitric oxide synthase (eNOS), has been implicated in atherosclerotic cardiovascular disease.However, the prognostic significance of baseline ADMA in the context of central obesity among patients with acute myocardial infarction (AMI) remains insufficiently characterized.ObjectivesThis study aimed to investigate whether central obesity (CO) is associated with elevated ADMA levels among patients with AMI in the Gaza Strip, Palestine.MethodsA comparative cross-sectional study was conducted at four governmental hospitals in the Gaza Strip. One hundred and twenty patients with a confirmed diagnosis of AMI aged 30–65 years were recruited via convenience sampling between January 2023 and October 2023.Anthropometric parameters, including Body Mass Index (BMI) and Waist Circumference (WC), biochemical measurements such as ADMA, homocysteine (Hcy), and lipid profile, and lifestyle factors were assessed.Group differences were evaluated using independent-samples t-tests. Pearson correlations and Multiple linear regression were employed to explore inter-variable relationships.ResultsOf 120 AMI patients, 102 (85.0%) were male, and 18 (15.0%) were female (mean age 53.49 ± 7.35 years). Central obesity (WC >102 cm in men; >88 cm in women) was present in 53.3% of participants. Statistically significant differences between the centrally obese and non-obese groups were observed for total cholesterol (P = 0.030), triglycerides (P = 0.048), and HDL-c (P = 0.043). ADMA and Hcy levels were significantly higher in the centrally obese group than in the non-obese group (differences: 35.1 ng/mL and 7.7 µmol/L, respectively; P = 0.040 and P = 0.009). Multiple Linear Regression identified WC as the only significant independent predictor of ADMA (β = 1.22, 95% CI 0.003- 2.445, P = 0.049).ConclusionsWC was significantly associated with elevated ADMA levels in patients with AMI. Given the cross-sectional design, these findings should be regarded as preliminary, and further longitudinal studies are needed to confirm whether central obesity contributes to elevated ADMA and cardiovascular risk.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12872-026-06178-w.Keywords: Asymmetric dimethylarginine, Central obesity, Acute myocardial infarction, Waist circumference, Gaza Strip Background Plasma asymmetric dimethylarginine (ADMA) is recognized as a biomarker of atherosclerotic cardiovascular disease (CVD) risk and mortality [1]. Acting as a non-selective inhibitor of nitric oxide synthases (NOS), ADMA reduces the synthesis of nitric oxide (NO), a molecule crucial for endothelial vasodilatation, prevents platelet aggregation, and regulates leukocyte adhesion [2]. Under normal conditions, NO is synthesized in small amounts by endothelial NOS (eNOS); however, during acute and chronic inflammation, activation of inducible NOS (iNOS) may lead to excessive NO production, promoting oxidative stress, damage of the blood vessel lining, and consequent injury to both the endothelium and myocytes [3, 4]. ADMA plasma concentrations are elevated across a spectrum of cardiovascular risk states, including hypertension (HTN), hypercholesterolemia, type 2 diabetes mellitus (T2DM), hyperhomocysteinemia, and end-stage renal failure [5, 6]. Importantly, ADMA has been established as an independent CVD risk factor, with the highest quartile of plasma ADMA conferring a 3.9-fold increased risk of acute coronary events in prospective studies [7]. Furthermore, patients with baseline ADMA in the highest tertile exhibited a 2.48-fold risk for future cardiovascular events over a mean follow-up of 2.6 years [8]. Obesity, particularly abdominal obesity, is associated with chronic low-grade inflammation characterized by pro-inflammatory macrophage accumulation in adipose tissue and upregulated iNOS expression [9, 10]. Elevated serum NO concentrations and markers of nitrosative and oxidative stress have been observed in overweight and obese adults [11]. The cardiovascular consequences of obesity include accelerated atherosclerosis, ventricular remodeling, and increased rates of associated diseases such as stroke, acute myocardial infarction, and heart failure [12]. Myocardial infarction is defined as myocardial cell necrosis resulting from prolonged ischemia, driven by an imbalance between oxygen supply and demand [13]. Dyslipidemia, encompassing elevated low-density lipoprotein cholesterol (LDL-c) and triglycerides (TG), and elevated serum homocysteine (Hcy), is an established contributor to coronary artery disease (CAD) progression and myocardial injury [14, 15]. Despite growing evidence linking ADMA to cardiovascular disease risk, the specific relationship between ADMA levels and central obesity in patients with acute myocardial infarction remains unclear, particularly in conflict-affected, resource-limited areas such as the Gaza Strip. Therefore, this study was conducted to investigate whether elevated ADMA levels are associated with central obesity in patients with acute myocardial infarction. Methods Study design and setting In an effort to enhance understanding of cardiac health services in the Gaza Strip, an analytical, comparative, cross-sectional study was conducted across four prominent governmental hospitals: Al-Shifa Medical Complex in Gaza City, Nasser Medical Complex in Khan Younis, Al-Aqsa Martyrs Hospital in the Middle Governorate, and the Indonesian Hospital in the Northern Governorate. Data were collected from January 2023 to October 2023. Participants The target population comprised all adult Palestinians aged 30–65 years with a confirmed diagnosis of AMI. Inclusion criteria were: (1) male or female patients aged 30–65 years; and (2) hospitalization in a governmental cardiac unit with a confirmed AMI diagnosis. Patients were excluded if they were receiving vitamin B12, folate, or methionine loading therapy; had diagnosed renal impairment; or refused written informed consent. Patients on vitamin B12 supplements were excluded because B12 is a cofactor in the remethylation of homocysteine to methionine, directly modulating the S-adenosylmethionine (SAM) / S-adenosylhomocysteine (SAH) cycle that drives arginine methylation and ADMA synthesis (Fig. 1), thereby confounding the measured ADMA levels. Similarly, patients on a methionine load were excluded as excess methionine raises SAM availability, the methyl donor for ADMA formation, artificially elevating ADMA independent of central obesity [16]. Schematic of the biochemical pathways linking the methionine methylation cycle to ADMA and vascular disease. S-adenosylmethionine (SAM) serves as the methyl donor; N-methyltransferases transfer two methyl groups onto L-arginine to form methyl-L-arginine, and proteolysis liberates free ADMA. ADMA is degraded by DDAH to L-citrulline, excreted in urine, and competitively inhibits NO synthase, ultimately driving endothelial dysfunction and vascular disease Sample size and sampling Sample size was calculated using the formula n = Z²pq/d², where Z = 1.96 (95% confidence), p = 0.126 (estimated obesity prevalence among AMI patients) [17], d = 0.05, and a 10% non-response adjustment, yielding a target of 186 participants. Only 120 cases were recruited due to the start of the aggression against Gaza in October 2023. Non-probability convenience sampling was applied, with proportional allocation across hospitals based on monthly AMI case volume. Data collection instruments A structured interview-administered questionnaire captured five domains: (1) socio-demographic and socio-economic charactesitcs; (2) medical and lifestyle history including smoking status and dietary intake patterns; (3) physical activity, assessed via the International Physical Activity Questionnaire short form (IPAQ) [18], which classifies participants into low, moderate, and high physical activity categories ; (4) anthropometric measurements; and (5) biochemical data. All participants provided written informed consent before data collection began. Anthropometric measurements Body weight was measured using a SECA digital electronic weighing scale (to the nearest 0.1 kg), with participants wearing minimal clothing and no footwear. Height was measured using a calibrated SECA stadiometer (nearest 0.5 cm). Body mass index (BMI) was calculated as weight (kg) divided by height squared (m²). BMI categories followed WHO classifications: underweight (< 18.5), normal weight (18.5–24.9), overweight (25–29.9), and obese (≥ 30 kg/m²) [19]. Waist circumference (WC) was measured at the midpoint between the last palpable rib and the iliac crest using a constant-tension, stretch-resistant tape. Central obesity was defined as WC > 102 cm in men and > 88 cm in women [19]. All measurements were performed in duplicate, and the mean value was recorded. Biochemical measurements Blood samples were collected after an overnight fast of 8–10 h. ADMA was quantified using a sandwich enzyme-linked immunosorbent assay (ELISA) on a Mindray MR-96 A plate reader (ADMA ELISA kit; Catalog No: abx150315, Abbexa UK, reference range 15.6–1000 ng/mL; sensitivity 9.38 ng/mL). Homocysteine (Hcy) was measured using a Homocystein ELISA kit (Catalog No: abx576699, Abbexa UK; reference range 98.77 ng/ml − 8000 ng/ml). Total cholesterol, TG, and HDL-c were measured on a Mindray BS-120 automated chemistry analyzer using Accucare and BioMaxima reagents (Poland). LDL-c was calculated using the Friedewald equation: LDL-c = Total cholesterol − HDL-c − (TG/5.0) mg/dL [20]. Statistical analysis Data were analyzed using SPSS version 26. Descriptive statistics were expressed as mean ± standard deviation (SD) for continuous variables and as frequencies (n) and percentages (%) for categorical variables. Normality was assessed using the Shapiro-Wilk test. Group differences between centrally obese and non-obese participants were compared using independent-samples t-tests. Pearson correlation coefficients were computed to examine relationships between lipid profile parameters, ADMA, and Hcy. Simple linear regression was performed to identify independent predictors of ADMA. The level of statistical significance was set at P < 0.05. Ethical approval This study was approved by the Institutional Review Board (IRB) of Al-Azhar University-Gaza, AUG- 2022- CN312, and by the Research Ethics Committee of the Palestinian Ministry of Health, Gaza Strip, R422630. Written informed consent was obtained from all participants before data collection, following a full explanation of the study objectives, procedures, voluntary nature of participation, and the right to withdraw at any time without consequence. All data were collected and handled anonymously to ensure participant confidentiality. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. Results Socio-demographic and clinical characteristics Table 1 indicates that 120 patients with confirmed AMI were enrolled. The mean age of participants is 53.49 ± 7.35 years. The sample was predominantly male (85%), with large average household sizes (8.30 ± 2.91 persons) and 83.4% living below the deep poverty line, indicating a highly economically vulnerable population. Table 1Socio-demographic characteristics of all participants (N = 120)Variablen (%)Mean ± SDAge (years)53.49 ± 7.35 Gender – Male102 (85.0) Gender – Female18 (15.0)Household size (persons)8.30 ± 2.91Total Household Income >1973 NISa100 (83.4) 1973–2470 NISb10 (8.3) <2470 NISc10 (8.3)Educational Level Uneducated10 (8.3) Primary7 (5.8) Preparatory29 (24.2) Secondary43 (35.8) University31 (25.8)a = deep poverty, b = poor and c = not poor Socio-demographic characteristics of all participants (N = 120) a = deep poverty, b = poor and c = not poor Educationally, the majority of participants held secondary (35.8%) or university-level (25.8%) qualifications, despite the high poverty rate, suggesting that underemployment may be a key issue rather than a lack of education. Medical history, lifestyle, and dietary characteristics As shown in Table 2, the majority of participants had no hypertension (64.2%) or type 2 diabetes mellitus (66.7%), while over half reported a positive family history of cardiac disease (53.3%) and current smoking (57.5%), with hypertension being the only comorbidity that differed significantly between groups (p < 0.001). Most participants were classified as having low (51.7%) or moderate (42.5%) physical activity levels, with only 5.8% achieving high activity, consistent with the IPAQ score not reaching significance in the regression model. Fewer than one in five participants followed a dietary regimen (18.3%), a notably low rate given the cardiovascular context of the study population. The high prevalence of smoking and positive family history suggests that this cohort carries a substantial background cardiovascular risk burden beyond the metabolic variables examined. Table 2Medical history and lifestyle characteristics of all the participantsVariablen (%)Mean ± SDHypertension*** Yes43 (35.8) No77(64.2)Type 2 diabetes mellitus Yes40 (33.3) No80(66.7)Family history of cardiac disease Yes64 (53.3) No56(46.7)Diet Regimen Yes22(18.3) No98(81.7)Smoking Status Yes69 (57.5) No51 (42.5)Classes of Physical Activity Low62 (51.7) Moderate51 (42.5) High7 (5.8)*** There was a significant association between the CO and the Non-CO Medical history and lifestyle characteristics of all the participants *** There was a significant association between the CO and the Non-CO Anthropometric measurements Table 3 shows that the mean BMI was 28.66 ± 5.70 kg/m². Most participants were overweight (35.0%) or obese (34.2%). The mean WC was 102.58 ± 14.40 cm overall (103.09 cm in men; 99.72 cm in women). Central obesity, defined by elevated WC, was present in 53.3% of participants. Table 3Anthropometric measurements of all participants (N = 120)Variablen (%)Mean ± SDBody weight (kg)83.32 ± 16.32Height (cm)171.0 ± 10.2BMI (kg/m²)28.66 ± 5.70 Underweight (< 18.5)1 (0.8) Normal weight (18.5–24.9)36 (30.0) Overweight (25–29.9)42 (35.0) Obese (≥ 30)41 (34.2)Waist circumference (cm)102.58 ± 14.40 Normal WC56 (46.7) WC (central obesity)64 (53.3)BMI Body mass index, WC Waist circumference (elevated threshold: >102 cm men; >88 cm women) Anthropometric measurements of all participants (N = 120) BMI Body mass index, WC Waist circumference (elevated threshold: >102 cm men; >88 cm women) Biochemical and CVDs markers Table 4 shows the biochemical and CVD markers. Table 4Biochemical and CVD markers of all participants (N = 120)Variablen (%)Mean ± SDADMA (ng/mL)108.63 ± 93.97Normal (≥ 15.6 ng/mL)119 (99.2)Low (< 15.6 ng/mL)1 (0.8)Hcy (µmol/L)13.56 ± 17.09 Normal (≤ 15 µmol/L)93 (77.5) Elevated (> 15 µmol/L)27 (22.5) Total cholesterol (mg/dL)175.5 ± 49.51 Normal (< 200 mg/dL)88 (73.3) Elevated (≥ 200 mg/dL)32 (26.7)Triglycerides (mg/dL)195.92 ± 123.03 Normal (< 150 mg/dL)55 (45.8) Elevated (≥ 150 mg/dL)65 (54.2)HDL-c (mg/dL)40.95 ± 8.86 Normal (≥ 35 mg/dL)63 (52.5) Low (< 35 mg/dL)57 (47.5)LDL-c (mg/dL)95.28 ± 47.45 Normal (< 100 mg/dL)71 (59.2) Elevated (≥ 100 mg/dL)49 (40.8)ADMA Asymmetric dimethylarginine, Hcy Homocysteine, HDL-c High-density lipoprotein cholesterol, LDL-c Low-density lipoprotein cholesterol Biochemical and CVD markers of all participants (N = 120) ADMA Asymmetric dimethylarginine, Hcy Homocysteine, HDL-c High-density lipoprotein cholesterol, LDL-c Low-density lipoprotein cholesterol The mean serum ADMA was 108.63 ± 93.97 ng/mL, and almost one-fourth of participants had high ADMA levels above the normal range. The mean Hcy was 13.56 ± 17.09 µmol/L, and 22.5% of participants had elevated Hcy (> 15 µmol/L). Mean total cholesterol was 175.5 ± 49.51 mg/dL, TG was 195.92 ± 123.03 mg/dL, HDL-c was 40.95 ± 8.86 mg/dL, and LDL-c was 95.28 ± 47.45 mg/dL. Elevated TG was present in 54.2% of participants, and low HDL-c in 47.5%. Lipid profile comparison and CVD markers between waist circumference groups Table 5 reportes that the centrally obese participants had significantly higher total cholesterol (184.6 ± 51.63 vs. 165.1 ± 45.17 mg/dL; t = − 2.197, P = 0.030) and the median and the IQR of TG (153.50 (105.50) vs. 181.50 (136.75) mg/dL; z = -2.20, P = 0.027), and significantly lower HDL-c (39.4 ± 8.80 vs. 42.7 ± 8.71 mg/dL; t = 2.043, P = 0.043). LDL-c was higher in the centrally obese group (101.7 ± 52.72 vs. 87.9 ± 39.79 mg/dL), though the difference was not statistically significant (P = 0.105). Table 5Comparison of lipid profile and CVD markers between waist circumference groupsVariableNon-CO Group (n = 56) Mean ± SDCO Group (n = 64) Mean ± SDt-valueP-valueTotal cholesterol (mg/dL)165.1 ± 45.17184.6 ± 51.63−2.1970.030*Triglycerides (mg/dL)172.3 ± 112.03216.6 ± 129.23−1.9960.048*HDL-c (mg/dL)42.7 ± 8.7139.4 ± 8.802.0430.043*LDL-c (mg/dL)87.9 ± 39.79101.7 ± 52.72−1.6320.105ADMA (ng/mL)89.9 ± 94.65125.0 ± 90.94−2.0730.040*Hcy (µmol/L)9.5 ± 4.2617.2 ± 2.52−2.6850.009*CO Central obesity, HDL-c High-density lipoprotein cholesterol, LDL-c Low-density lipoprotein cholesterol, ADMA Asymmetric dimethylarginine, Hcy Homocysteine. Independent-sample t-test *P < 0.05 Comparison of lipid profile and CVD markers between waist circumference groups CO Central obesity, HDL-c High-density lipoprotein cholesterol, LDL-c Low-density lipoprotein cholesterol, ADMA Asymmetric dimethylarginine, Hcy Homocysteine. Independent-sample t-test *P < 0.05 Table 5 also reported that both ADMA and Hcy were significantly elevated in the centrally obese group. The median and IQR of ADMA were 90.90 (99.50) ng/mL in the high-WC group compared with 58.35 (39.62) ng/mL in the normal-WC group (Z = -3.28, P = 0.001). Hcy was 17.2 ± 2.52 µmol/L versus 9.5 ± 4.26 µmol/L (t = − 2.685, P = 0.009) . Correlations between lipid parameters, ADMA, and Hcy Pearson correlation analysis in Table 6 revealed no statistically significant correlations between lipid profile parameters (total cholesterol, TG, HDL-c, LDL-c) and serum ADMA (r = 0.007, P = 0.939; r = 0.146, P = 0.111; r = − 0.055, P = 0.554; r = − 0.057, P = 0.534, respectively). Similarly, no significant correlations were found between lipid parameters and Hcy. No significant correlation was observed between Hcy and ADMA (r = 0.161, P = 0.079). Table 6Pearson correlation between lipid profile parameters and serum ADMALipid ParameterPearson rP-valueTotal cholesterol0.0070.939Triglycerides0.1460.111HDL-c−0.0550.554LDL-c−0.0570.534ADMA Asymmetric dimethylarginine, HDL-c High-density lipoprotein cholesterol, LDL-c Low-density lipoprotein cholesterol Pearson correlation between lipid profile parameters and serum ADMA ADMA Asymmetric dimethylarginine, HDL-c High-density lipoprotein cholesterol, LDL-c Low-density lipoprotein cholesterol Predictors of ADMA Table 7 shows that Simple linear regression identified WC as a significant predictor of serum ADMA (β = 1.532, 95% CI: 0.376–2.689, P = 0.010). Forward stepwise multiple linear regression, entering WC, BMI, age, gender, IPAQ score, total cholesterol, triglycerides, HDL-c, and Hcy as candidate predictors, confirmed WC as the sole independent predictor, with no additional variable meeting the entry criterion (P < 0.05). The final model accounted for 2.7% of the variance in serum ADMA (Adjusted R² = 0.027, p = 0.201). Waist circumference was the only independent predictor of serum ADMA. For every 1 cm increase in waist circumference, ADMA increases by 1.224 µmol/L after adjusting for age, gender, physical activity, triglycerides, HDL-c, LDL-c, and homocysteine. Table 7Linear regression model of the predictors of serum ADMA levelVariableSimple Linear RegressionMultiple Linear RegressionβSE95% CIP-valueβ95% CIP-valueWaist circumference (cm)1.530.580.37–2.680.010*1.2240.003–2.4450.049BMI (kg/m²)2.971.490.02–5.920.048*Age (years)0.031.17−2.29–2.360.974Gender2.9924.12−44.77–50.760.901IPAQ score−0.020.028−0.07–0.020.398Total cholesterol0.0130.175−0.333–0.3590.939Triglycerides0.1120.070−0.026–0.2490.111HDL-c−0.5790.975−2.510–1.3520.554LDL-c−0.1130.182−0.474–0.2470.534Hcy (µmol/L)0.8850.500−0.104–1.8750.079HTN−22.50920.495[− 63.1, 18.1]0.274LDL-c was excluded from the full model due to perfect multicollinearity with total cholesterol and triglyceridesSimple linear regression. Dependent variable: serum ADMABMI Body mass index, Hcy Homocysteine, HDL-c High-density lipoprotein cholesterol, IPAQ International Physical Activity Questionnaire, LDL-c Low-density lipoprotein cholesterol, SE Standard errorFull model: F(9,110) = 1.323, P = 0.233; R² = 0.098; Adjusted R² = 0.024*P < 0.05 Linear regression model of the predictors of serum ADMA level LDL-c was excluded from the full model due to perfect multicollinearity with total cholesterol and triglycerides Simple linear regression. Dependent variable: serum ADMA BMI Body mass index, Hcy Homocysteine, HDL-c High-density lipoprotein cholesterol, IPAQ International Physical Activity Questionnaire, LDL-c Low-density lipoprotein cholesterol, SE Standard error Full model: F(9,110) = 1.323, P = 0.233; R² = 0.098; Adjusted R² = 0.024 *P < 0.05 Discussion To the best of our knowledge, this is the first study to examine the association between central obesity and ADMA levels among AMI patients in the Gaza Strip, Palestine, a setting of particular clinical relevance given the high burden of CVD and constrained healthcare resources [21]. The principal finding is that WC is a significant, independent, and modifiable predictor of elevated serum ADMA in this population. The observed dyslipidaemic profile in centrally obese AMI patients, higher total cholesterol, elevated TG, and lower HDL-c, is consistent with published literature. A study of obese and coronary heart disease (CHD) patients reported that 80.4% had TG above the normal range and 64% had HDL-c in the moderate CHD risk range [22]. Dyslipidemia, particularly hypertriglyceridemia and low HDL-c, constitutes a major predisposing factor to obesity, T2DM, and CVD [23, 24]. Epidemiological evidence consistently demonstrates that a co-occurrence of low HDL-c and elevated TG amplifies CHD risk [25, 26]. A statistically significant difference in Hcy levels was reported between the centrally obese and non-obese AMI groups (P-value = 0.009). This is consistent with meta-analytic evidence showing a significant association between Hcy and obesity, although the exact direction of causality remains unclear [27]. Central obesity has been specifically reported to correlate positively with hyperhomocysteinemia, while general obesity showed an inverse trend [28]. Hcy, a sulfur-containing intermediate of methionine metabolism, is increasingly recognized as a risk factor for CVD, T2DM, cerebrovascular disease, and insulin resistance [29–31]. Conversely, no significant correlations were identified between lipid parameters and Hcy in our cohort, consistent with prior reports in populations with diabetes and ischaemic heart disease [32, 33]. However, other studies have reported inverse associations between Hcy and HDL-c, mediated by inhibition of ApoA-I synthesis [34]. No statistically significant correlation was observed between Hcy and ADMA (r = 0.161, P = 0.079). This finding is consistent with reports by Jonasson et al. [35] and Wanby et al. [36], who demonstrated that hyperhomocysteinemia is not uniformly associated with elevated ADMA levels. Conflicting results in experimental models, ranging from a threefold elevation of ADMA in hyperhomocysteinaemic primates to only a minor elevation in cystathionine-β-synthase-deficient mice, underscore the complexity of this pathway [37]. The central finding of this study is a significant positive association between WC and serum ADMA, consistent with recent evidence. Krzyzanowska et al. demonstrated that weight loss in morbidly obese women significantly reduced circulating ADMA concentrations [38]. ADMA is negatively correlated with serum NO concentration and modifies the association between Trans Fatty Acids (TFA) and cardiovascular mortality or morbidity [39]. ADMA inhibits eNOS, reducing NO bioavailability and thereby contributing to endothelial dysfunction in obesity [40, 41]. ADMA has been proposed as a mechanistic link between systemic low-grade inflammation and endothelial dysfunction in humans, since proinflammatory and pro-oxidant stimuli both suppress DDAH-mediated ADMA degradation and enhance its synthesis, raising circulating ADMA [42]. A clinical study demonstrated reduced NO-dependent vasodilation in obese compared with lean subjects [43]. The mechanism linking obesity to elevated ADMA likely involves TNF-α-induced suppression of dimethylarginine dimethylaminohydrolase (DDAH), the primary ADMA-degrading enzyme [44]. This is consistent with the previously reported relationship between ADMA and high-sensitivity CRP [45]. Strengths and limitations This study provides novel evidence from a conflict-affected, resource-limited setting and comprehensively characterizes the relationship between central obesity, dyslipidemia, Hcy, and ADMA in AMI patients. Limitations include the cross-sectional design, which precludes causal inference. Dietary assessment was limited to meal frequency data and did not include detailed nutrient intake. As an exploratory study, the sample size was modest and resource-constrained; though adequate for the primary comparisons, it limits statistical power and generalizability. The lack of data on participants’ medication use is a further limitation, as certain drugs may influence ADMA levels and were not available for adjustment. Conclusions This study demonstrates that central obesity, as measured by waist circumference, is a significant independent predictor of elevated serum ADMA in AMI patients from the Gaza Strip. Centrally obese AMI patients had significantly higher ADMA, Hcy, total cholesterol, and TG, and lower HDL-c than their non-obese counterparts. The observed association between central obesity and ADMA suggests that abdominal adiposity, a modifiable risk factor, may be linked to endothelial dysfunction in patients at risk for AMI. Whether reducing abdominal adiposity lowers ADMA levels warrants investigation in future longitudinal or interventional studies. These findings have clinical implications for lifestyle intervention programs targeting cardiovascular risk reduction in similar resource-limited settings. Supplementary Information Supplementary Material 1. Acknowledgements The authors gratefully acknowledge the study participants for their time and cooperation. We thank the medical and nursing teams of the four governmental hospitals and all participating governmental hospitals in the Gaza Strip for their invaluable support during data collection. We also acknowledge the Institute of International Education – Scholar Rescue Fund (IIE-SRF) and the University of Alberta for supporting one of the co-authors. AI The authors acknowledge the use of AI-based tools (Grammarly) for text editing purposes only. The authors take full responsibility for the integrity and originality of the scientific content. Abbreviations Asymmetric dimethylarginine Acute myocardial infarction Body mass index Coronary artery disease Central obesity Cardiovascular disease Dimethylarginine dimethylaminohydrolase Diabetes mellitus Endothelial nitric oxide synthase Homocysteine High-density lipoprotein cholesterol Hypertension Inducible nitric oxide synthase International Physical Activity Questionnaire Low-density lipoprotein cholesterol Nitric oxide Nitric oxide synthases Type 2 diabetes mellitus Triglycerides Waist circumference World Health Organization Authors' contributions AMAA contributed to study conception, data collection, data analysis, and manuscript drafting. RKAQ contributed to the study design, oversight of biochemical analyses, and manuscript revision. IAN contributed to the conception of the study, supervision, statistical guidance, and critical revision of the manuscript. All authors read and approved the final manuscript. Funding No specific funding was received for this study. Data availability The data generated and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was conducted in accordance with the Declaration of Helsinki. Written institutional approval was obtained from Al-Azhar University-Gaza and the Palestinian Ministry of Health. Written informed consent was obtained from all participants prior to enrolment. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The data generated and/or analyzed during the current study are available from the corresponding author on reasonable request.